- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
- Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
- Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Announces Updates to Operations Leadership
- Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
- Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
- Liquidia Corporation Announces $100 Million in New Financings
More ▼
Key statistics
On Wednesday, Liquidia Corp (LQDA:NAQ) closed at 12.55, -26.13% below its 52-week high of 16.99, set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.97 |
---|---|
High | 13.07 |
Low | 12.40 |
Bid | 11.50 |
Offer | 13.75 |
Previous close | 12.55 |
Average volume | 934.03k |
---|---|
Shares outstanding | 76.03m |
Free float | 66.60m |
P/E (TTM) | -- |
Market cap | 954.15m USD |
EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼